Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)
A phase 2 trial of BO-112 in basal cell carcinoma, run by Highlight Therapeutics, active and no longer recruiting.
Overview
Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) is a phase 2 interventional study registered as NCT06422936 by Highlight Therapeutics, with 60 participants enrolled, started 2024-05-27 and due to reach its primary completion in 2026-06. Interventions recorded: BO-112.
Setting
SPOTLIGHT 204: A Multicenter, Phase 2b, Open-label, Non-randomized, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Intra-lesional BO-112 in Patients With Resectable Primary Low and High Risk Basal Cell Carcinoma
Phase
Phase 2
Sponsor
Highlight Therapeutics
Registry
Enrolled
60
Similar pages
not linked directly; found by shared links- TrialEfficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Shares Basal cell carcinoma and the tag pipeline.
- TrialPlacebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
Shares Basal cell carcinoma and the tag pipeline.
- TrialL19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Shares Basal cell carcinoma and the tag pipeline.
- TrialL19IL2/TNF in Patients With Basal Cell Carcinoma
Shares Basal cell carcinoma and the tag pipeline.
- TrialStudy to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
Shares Basal cell carcinoma and the tag pipeline.